The Epilepsy Therapeutics Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Medical Advances Driving Epilepsy Treatment Market Growth
In the ever-evolving field of medical progress, initiatives and innovations in epilepsy treatment are playing a pivotal role in reshaping patient care paradigms. Globally, government-backed endeavors and cutting-edge developments in drugs and treatments are fostering an environment of unprecedented growth in the epilepsy treatment market. A notable initiative occurred when NYU Langone Health secured an $8 million grant from the National Institutes of Health (NIH) in February 2022. The funds are earmarked to develop an innovative implantable monitoring device designed to capture unprecedented data on brain activity during seizures. Led by Dr. Daniel Friedman at NYU Langone’s Comprehensive Epilepsy Center, the project addresses the limitations of outdated technology, presenting an opportunity to build an ultrathin device with thousands of measurement contacts. This NIH UG3/UH3-funded initiative involves collaboration with institutions such as New York University’s Center for Neural Science, Duke University, the University of Utah, and Blackrock Neurotech.
Designed by Dr. Jonathan Viventi from Duke University, the implant utilizes flexible liquid crystal polymer thermoplastic material and a network of circuits connecting hundreds to thousands of electrodes for high-density sampling of microsignals from extensive brain areas. Successfully tested intraoperatively, the device is poised for clinical use with the capacity for implantation for up to 30 days. As part of the NIH’s Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, this collaborative effort places NYU Langone Health at the forefront of transformative advancements in epilepsy care. Clinical trials employing an FDA-approved monitoring implant are expected to commence in 2023, contributing to the growth of the epilepsy treatment market by fostering groundbreaking advancements in laser ablation, high-precision surgeries, and overall improvements in epilepsy treatment outcomes.
Socioeconomic Disparities and Technological Challenges
A global concern is the accessibility of anti-seizure medication, with many individuals facing difficulties in affording or obtaining multiple medication options, as emphasized in the August 2022 report, ‘Survey on the worldwide availability and affordability of anti-seizure medications: Report of the ILAE Task Force on Access to Treatment.’ Beyond medication-related challenges, demographic factors contribute significantly to differences in the quality of life and care experiences of individuals. Studies conducted in the United States and North America reveal disparities in seizure control rates and epilepsy remission along racial and ethnic lines. Additionally, there are delays in diagnosis and reduced utilization of epilepsy surgery in specific minority populations.
Furthermore, as highlighted in an article published in December 2022 by NIH, the impact of socioeconomic and racial divides extends to rates of sudden unexpected death in epilepsy (SUDEP). Individuals facing high socioeconomic disadvantage exhibit higher rates of SUDEP, persisting even during periods of decreasing overall SUDEP rates. The identified barriers to care, including medication affordability and access to primary and specialist care, demand comprehensive solutions that extend beyond the healthcare sector. Addressing these issues necessitates not only healthcare interventions but also broader political, economic, and systemic changes. While promising strategies like telehealth services are emerging, sustainable solutions will require coordinated efforts involving individuals, communities, healthcare institutions, and governmental and non-governmental organizations. This underscores the complex and multifaceted nature of the challenges in epilepsy care.
What Questions Should You Ask before Buying a Market Research Report?
- How is the epilepsy therapeutics market evolving?
- What is driving and restraining the epilepsy therapeutics market?
- How will each epilepsy therapeutics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
- How will the market shares for each epilepsy therapeutics submarket develop from 2024 to 2034?
- What will be the main driver for the overall market from 2024 to 2034?
- Will leading epilepsy therapeutics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
- Who are the leading players and what are their prospects over the forecast period?
- What are the epilepsy therapeutics projects for these leading companies?
- How will the industry evolve during the period between 2024 and 2034? What are the implications of epilepsy therapeutics projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further the epilepsy therapeutics?
- Where is the epilepsy therapeutics market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Epilepsy Therapeutics Market today, and over the next 10 years:
- Our 215-page report provides 91 tables, 119 charts /graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them – NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the Epilepsy Therapeutics Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2034 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising epilepsy therapeutics prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
Drug Class
- First Generation Drugs
- Second Generation Drugs
- Third Generation Drugs
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 25 leading national markets:
North America
Europe
- Germany
- UK
- France
- Spain
- Italy
- Sweden
- Switzerland
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Singapore
- Taiwan
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
MEA
- GCC
- South Africa
- Rest of MEA
Need industry data? Please contact us today.
The report also includes profiles and for some of the leading companies in the Epilepsy Therapeutics Market, 2024 to 2034, with a focus on this segment of these companies’ operations.
Leading companies profiled in the report
- Eisai, Inc.
- GlaxoSmithKline (GSK)
- GW Pharma
- Merk KGaA
- Neurocrine Biosciences, Inc.
- Novartis AG
- Ovid Therapeutics
- Pfizer Inc
- Praxis Precision Medicines
- Sanofi
- UCB S.A.
Overall world revenue for Epilepsy Therapeutics Market, 2024 to 2034 in terms of value the market will surpass US$9,800 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Epilepsy Therapeutics Market, 2024 to 2034 report help you?
In summary, our 210+ page report provides you with the following knowledge:
- Revenue forecasts to 2034 for Epilepsy Therapeutics Market, 2024 to 2034, with forecasts for drug class and distribution channel each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2034 for five regional and 25 key national markets – See forecasts for the Epilepsy Therapeutics Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Germany, UK, France, Spain, Italy, Sweden, Switzerland, China, India, Japan, Australia, South Korea, Singapore, Taiwan, Brazil, Mexico, Argentina, GCC, South Africa, and among other prominent economies.
- Prospects for established firms and those seeking to enter the market – including company profiles for 10 of the major companies involved in the Epilepsy Therapeutics Market, 2024 to 2034.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Epilepsy Therapeutics Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Epilepsy Therapeutics Market Report 2024-2034: Forecasts by Drug Class (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com
1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Epilepsy Therapeutics Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Transforming Brain Tumour-Related Epilepsy through Innovative Gene Therapy Approaches
3.2.1.2 Uncovering Novel Possibilities in a Rare Form of Childhood Epilepsy Treatment
3.2.1.3 Advancements, Global Investments, and Medical Advances Drive Epilepsy Treatment Market Growth
3.2.1.4 Surge in Epilepsy Prevalence
3.2.2 Market Restraining Factors
3.2.2.1 Seizure Recognition Challenges
3.2.2.2 Socioeconomic Disparities and Technological Challenges
3.2.2.3 Patent Expiry
3.2.3 Market Opportunities
3.2.3.1 Innovating Antiepileptic Therapies for Drug-Resistant Cases
3.2.3.2 Inhibitory Neurons Transform Focal Epilepsy Treatment
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
4 Epilepsy Therapeutics Market Analysis by Drug Class
4.1 Key Findings
4.2 Drug Class Segment: Market Attractiveness Index
4.3 Epilepsy Therapeutics Market Size Estimation and Forecast by Drug Class
4.4 First Generation Drugs
4.4.1 Market Size by Region, 2024-2034 (US$ Million)
4.4.2 Market Share by Region, 2024 & 2034 (%)
4.5 Second Generation Drugs
4.5.1 Market Size by Region, 2024-2034 (US$ Million)
4.5.2 Market Share by Region, 2024 & 2034 (%)
4.6 Third Generation Drugs
4.6.1 Market Size by Region, 2024-2034 (US$ Million)
4.6.2 Market Share by Region, 2024 & 2034 (%)
5 Epilepsy Therapeutics Market Analysis by Distribution Channel
5.1 Key Findings
5.2 Distribution Channel Segment: Market Attractiveness Index
5.3 Epilepsy Therapeutics Market Size Estimation and Forecast by Distribution Channel
5.4 Hospital Pharmacy
5.4.1 Market Size by Region, 2024-2034 (US$ Million)
5.4.2 Market Share by Region, 2024 & 2034 (%)
5.5 Retail Pharmacy
5.5.1 Market Size by Region, 2024-2034 (US$ Million)
5.5.2 Market Share by Region, 2024 & 2034 (%)
5.6 Online Pharmacy
5.6.1 Market Size by Region, 2024-2034 (US$ Million)
5.6.2 Market Share by Region, 2024 & 2034 (%)
6 Epilepsy Therapeutics Market Analysis by Region
6.1 Key Findings
6.2 Regional Market Size Estimation and Forecast
7 North America Epilepsy Therapeutics Market Analysis
7.1 Key Findings
7.2 North America Epilepsy Therapeutics Market Attractiveness Index
7.3 North America Epilepsy Therapeutics Market by Country, 2024, 2029 & 2034 (US$ Million)
7.4 North America Epilepsy Therapeutics Market Size Estimation and Forecast by Country
7.5 North America Epilepsy Therapeutics Market Size Estimation and Forecast by Drug Class
7.6 North America Epilepsy Therapeutics Market Size Estimation and Forecast by Distribution Channel
7.7 U.S. Epilepsy Therapeutics Market Analysis
7.8 Canada Epilepsy Therapeutics Market Analysis
8 Europe Epilepsy Therapeutics Market Analysis
8.1 Key Findings
8.2 Europe Epilepsy Therapeutics Market Attractiveness Index
8.3 Europe Epilepsy Therapeutics Market by Country, 2024, 2029 & 2034 (US$ Million)
8.4 Europe Epilepsy Therapeutics Market Size Estimation and Forecast by Country
8.5 Europe Epilepsy Therapeutics Market Size Estimation and Forecast by Drug Class
8.6 Europe Epilepsy Therapeutics Market Size Estimation and Forecast by Distribution Channel
8.7 Germany Epilepsy Therapeutics Market Analysis
8.8 France Epilepsy Therapeutics Market Analysis
8.9 UK Epilepsy Therapeutics Market Analysis
8.10 Italy Epilepsy Therapeutics Market Analysis
8.11 Spain Epilepsy Therapeutics Market Analysis
8.12 Sweden Epilepsy Therapeutics Market Analysis
8.13 Switzerland Epilepsy Therapeutics Market Analysis
8.14 Rest of Europe Epilepsy Therapeutics Market Analysis
9 Asia Pacific Epilepsy Therapeutics Market Analysis
9.1 Key Findings
9.2 Asia Pacific Epilepsy Therapeutics Market Attractiveness Index
9.3 Asia Pacific Epilepsy Therapeutics Market by Country, 2024, 2029 & 2034 (US$ Million)
9.4 Asia Pacific Epilepsy Therapeutics Market Size Estimation and Forecast by Country
9.5 Asia Pacific Epilepsy Therapeutics Market Size Estimation and Forecast by Drug Class
9.6 Asia Pacific Epilepsy Therapeutics Market Size Estimation and Forecast by Distribution Channel
9.7 Japan Epilepsy Therapeutics Market Analysis
9.8 China Epilepsy Therapeutics Market Analysis
9.9 India Epilepsy Therapeutics Market Analysis
9.10 Australia Epilepsy Therapeutics Market Analysis
9.11 South Korea Epilepsy Therapeutics Market Analysis
9.12 Singapore Epilepsy Therapeutics Market Analysis
9.13 Taiwan Epilepsy Therapeutics Market Analysis
9.14 Rest of Asia Pacific Epilepsy Therapeutics Market Analysis
10 Latin America Epilepsy Therapeutics Market Analysis
10.1 Key Findings
10.2 Latin America Epilepsy Therapeutics Market Attractiveness Index
10.3 Latin America Epilepsy Therapeutics Market by Country, 2024, 2029 & 2034 (US$ Million)
10.4 Latin America Epilepsy Therapeutics Market Size Estimation and Forecast by Country
10.5 Latin America Epilepsy Therapeutics Market Size Estimation and Forecast by Drug Class
10.6 Latin America Epilepsy Therapeutics Market Size Estimation and Forecast by Distribution Class
10.7 Brazil Epilepsy Therapeutics Market Analysis
10.8 Mexico Epilepsy Therapeutics Market Analysis
10.9 Argentina Epilepsy Therapeutics Market Analysis
10.10 Rest of Latin America Epilepsy Therapeutics Market Analysis
11 MEA Epilepsy Therapeutics Market Analysis
11.1 Key Findings
11.2 MEA Epilepsy Therapeutics Market Attractiveness Index
11.3 MEA Epilepsy Therapeutics Market by Country, 2024, 2029 & 2034 (US$ Million)
11.4 MEA Epilepsy Therapeutics Market Size Estimation and Forecast by Country
11.5 MEA Epilepsy Therapeutics Market Size Estimation and Forecast by Drug Class
11.6 MEA Epilepsy Therapeutics Market Size Estimation and Forecast by Application
11.7 GCC Epilepsy Therapeutics Market Analysis
11.8 South Africa Epilepsy Therapeutics Market Analysis
11.9 Rest of MEA Epilepsy Therapeutics Market Analysis
12 Company Profiles
12.1 Competitive Landscape, 2022
12.2 Strategic Outlook
12.1 Eisai, Inc.
12.1.1 Company Snapshot
12.1.2 Company Overview
12.1.3 Financial Analysis
12.1.3.1 Net Revenue, 2017-2022
12.1.3.2 Regional Market Shares, 2022
12.1.4 Product Benchmarking
12.1.5 Strategic Outlook
12.2 GlaxoSmithKline (GSK)
12.2.1 Company Snapshot
12.2.2 Company Overview
12.2.3 Financial Analysis
12.2.3.1 Net Revenue, 2017-2022
12.2.3.2 R&D, 2017-2022
12.2.3.3 Regional Market Shares, 2022
12.2.4 Product Benchmarking
12.2.5 Strategic Outlook
12.3 GW Pharma
12.3.1 Company Snapshot
12.3.2 Company Overview
12.3.3 Product Benchmarking
12.3.4 Strategic Outlook
12.4 Pfizer Inc
12.4.1 Company Snapshot
12.4.2 Company Overview
12.4.3 Financial Analysis
12.4.3.1 Net Revenue, 2017-2022
12.4.3.2 R&D, 2017-2022
12.4.3.3 Regional Market Shares, 2022
12.4.4 Product Benchmarking
12.4.5 Strategic Outlook
12.5 Sanofi
12.5.1 Company Snapshot
12.5.2 Company Overview
12.5.3 Financial Analysis
12.5.3.1 Net Revenue, 2017-2022
12.5.3.2 R&D, 2017-2022
12.5.3.3 Regional Market Shares, 2022
12.5.4 Product Benchmarking
12.5.5 Strategic Outlook
12.6 UCB S.A.
12.6.1 Company Snapshot
12.6.2 Company Overview
12.6.3 Financial Analysis
12.6.3.1 Net Revenue, 2017-2022
12.6.3.2 R&D, 2017-2022
12.6.3.3 Regional Market Shares, 2022
12.6.4 Product Benchmarking
12.6.5 Strategic Outlook
12.7 Novartis AG
12.7.1 Company Snapshot
12.7.2 Company Overview
12.7.3 Financial Analysis
12.7.3.1 Net Revenue, 2017-2022
12.7.3.2 R&D, 2017-2022
12.7.3.3 Regional Market Shares, 2022
12.7.4 Product Benchmarking
12.7.5 Strategic Outlook
12.8 Merck KGaA
12.8.1 Company Snapshot
12.8.2 Company Overview
12.8.3 Financial Analysis
12.8.3.1 Net Revenue, 2017-2022
12.8.3.2 R&D, 2017-2022
12.8.3.3 Regional Market Shares, 2022
12.8.4 Product Benchmarking
12.8.5 Strategic Outlook
12.9 Ovid Therapeutics
12.9.1 Company Snapshot
12.9.2 Company Overview
12.9.3 Product Benchmarking
12.9.4 Strategic Outlook
12.10 Praxis Precision Medicines
12.10.1 Company Snapshot
12.10.2 Company Overview
12.10.3 Product Benchmarking
12.10.4 Strategic Outlook
12.11 Neurocrine Biosciences, Inc.
12.11.1 Company Snapshot
12.11.2 Company Overview
12.11.3 Financial Analysis
12.11.3.1 Net Revenue, 2017-2022
12.11.3.2 R&D, 2017-2022
12.11.4 Product Benchmarking
12.11.5 Strategic Outlook
12.12 Neurelis, Inc.
12.12.1 Company Snapshot
12.12.2 Company Overview
12.12.3 Product Benchmarking
12.12.4 Strategic Outlook
13 Conclusion and Recommendations
13.1 Concluding Remarks from Visiongain
13.2 Recommendations for Market Players
List of Tables
Table 1 Epilepsy Therapeutics Market Snapshot, 2024 & 2034 (US$ million, CAGR %)
Table 2 Epilepsy Therapeutics Market Forecast by Region 2024-2034 (US$ Million, AGR%, CAGR%): "V" Shaped Recovery
Table 3 Epilepsy Therapeutics Market Forecast by Region 2024-2034 (US$ Million, AGR%, CAGR%): "U" Shaped Recovery
Table 4 Epilepsy Therapeutics Market Forecast by Region 2024-2034 (US$ Million, AGR%, CAGR%): "W" Shaped Recovery
Table 5 Epilepsy Therapeutics Market Forecast by Region 2024-2034 (US$ Million, AGR%, CAGR%): "L" Shaped Recovery
Table 6 Epilepsy Therapeutics Market Forecast by Drug Class, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 7 First Generation Drugs Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 8 Second Generation Drugs Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 9 Third Generation Drugs Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 10 Epilepsy Therapeutics Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 11 Hospital Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 12 Retail Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 13 Online Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 14 Epilepsy Therapeutics Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 15 North America Epilepsy Therapeutics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 16 North America Epilepsy Therapeutics Market Forecast by Drug Class, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 17 North America Epilepsy Therapeutics Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 18 U.S. Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 19 Canada Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 20 Europe Epilepsy Therapeutics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 21 Europe Epilepsy Therapeutics Market Forecast by Drug Class, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 22 North America Epilepsy Therapeutics Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 23 Germany Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 24 France Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 25 UK Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 26 Italy Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 27 Spain Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 28 Sweden Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 29 Switzerland Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 30 Rest of Europe Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 31 Asia Pacific Epilepsy Therapeutics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 32 Asia Pacific Epilepsy Therapeutics Market Forecast by Drug Class, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 33 Asia Pacific Epilepsy Therapeutics Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 34 Japan Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 35 China Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 36 India Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 37 Australia Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 38 South Korea Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 39 Singapore Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 40 Taiwan Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 41 Rest of Asia Pacific Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 42 Latin America Epilepsy Therapeutics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 43 Latin America Epilepsy Therapeutics Market Forecast by Drug Class, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 44 Latin America Epilepsy Therapeutics Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 45 Brazil Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 46 Mexico Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 47 Argentina Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 48 Rest of Latin America Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 49 MEA Epilepsy Therapeutics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 50 MEA Epilepsy Therapeutics Market Forecast by Drug Class, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 51 MEA Epilepsy Therapeutics Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 52 GCC Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 53 South Africa Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 54 Rest of MEA Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 55 Strategic Outlook
Table 56 Eisai, Inc. : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 57 Eisai, Inc.: Product Benchmarking
Table 58 Eisai, Inc.: Strategic Outlook
Table 59 GlaxoSmithKline (GSK): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 60 GlaxoSmithKline (GSK): Product Benchmarking
Table 61 GlaxoSmithKline (GSK): Strategic Outlook
Table 62 GW Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 63 GW Pharma : Product Benchmarking
Table 64 GW Pharma : Strategic Outlook
Table 65 Pfizer Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 66 Pfizer Inc : Product Benchmarking
Table 67 Pfizer Inc: Strategic Outlook
Table 68 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 69 Sanofi: Product Benchmarking
Table 70 Sanofi: Strategic Outlook
Table 71 UCB S.A.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 72 UCB S.A.: Product Benchmarking
Table 73 UCB S.A.: Strategic Outlook
Table 74 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 75 Novartis AG: Product Benchmarking
Table 76 Novartis AG: Strategic Outlook
Table 77 Merck KGaA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 78 Merck KGaA: Product Benchmarking
Table 79 Merck KGaA: Strategic Outlook
Table 80 Ovid Therapeutics : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 81 Ovid Therapeutics : Product Benchmarking
Table 82 Ovid Therapeutics: Strategic Outlook
Table 83 Praxis Precision Medicines: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 84 Praxis Precision Medicines: Product Benchmarking
Table 85 Praxis Precision Medicines: Strategic Outlook
Table 86 Neurocrine Biosciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 87 Neurocrine Biosciences, Inc.: Product Benchmarking
Table 88 Neurocrine Biosciences, Inc.: Strategic Outlook
Table 89 Neurelis, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 Neurelis, Inc.: Product Benchmarking
Table 91 Neurelis, Inc.: Strategic Outlook
List of Figures
Figure 1 Epilepsy Therapeutics Market Segmentation
Figure 2 Epilepsy Therapeutics Market by Drug Class: Market Attractiveness Index
Figure 3 Epilepsy Therapeutics Market by Distribution Channel: Market Attractiveness Index
Figure 4 Epilepsy Therapeutics Market Attractiveness Index by Region
Figure 5 Epilepsy Therapeutics Market: Market Dynamics
Figure 6 Epilepsy Therapeutics Market by Region, 2024-2034 (US$ Million, AGR %): “V” Shaped Recovery
Figure 7 Epilepsy Therapeutics Market by Region, 2024-2034 (US$ Million, AGR %): “U” Shaped Recovery
Figure 8 Epilepsy Therapeutics Market by Region, 2024-2034 (US$ Million, AGR %): “W” Shaped Recovery
Figure 9 Epilepsy Therapeutics Market by Region, 2024-2034 (US$ Million, AGR %): “L” Shaped Recovery
Figure 10 Epilepsy Therapeutics Market: Porter’s Five Forces Analysis
Figure 11 Epilepsy Therapeutics Market: PEST Analysis
Figure 12 Epilepsy Therapeutics Market by Drug Class: Market Attractiveness Index
Figure 13 Epilepsy Therapeutics Market Forecast by Drug Class, 2024-2034 (US$ Million, AGR %)
Figure 14 Epilepsy Therapeutics Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 15 First Generation Drugs Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 16 First Generation Drugs Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 17 Second Generation Drugs Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 18 Second Generation Drugs Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 19 Third Generation Drugs Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 20 Third Generation Drugs Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 21 Epilepsy Therapeutics Market by Distribution Channel: Market Attractiveness Index
Figure 22 Epilepsy Therapeutics Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 23 Epilepsy Therapeutics Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 24 Hospital Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 25 Hospital Pharmacy Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 26 Retail Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 27 Retail Pharmacy Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 28 Online Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 29 Online Pharmacy Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 30 Epilepsy Therapeutics Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)
Figure 31 Epilepsy Therapeutics Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 32 Epilepsy Therapeutics Market by Region, 2024-2034 (US$ Million, AGR %)
Figure 33 North America Epilepsy Therapeutics Market Attractiveness Index
Figure 34 North America Epilepsy Therapeutics Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 35 North America Epilepsy Therapeutics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 36 North America Epilepsy Therapeutics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 37 North America Epilepsy Therapeutics Market Forecast by Drug Class, 2024-2034 (US$ Million, AGR %)
Figure 38 North America Epilepsy Therapeutics Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 39 North America Epilepsy Therapeutics Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 40 North America Epilepsy Therapeutics Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 41 U.S. Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 42 Canada Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 43 Europe Epilepsy Therapeutics Market Attractiveness Index
Figure 44 Europe Epilepsy Therapeutics Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 45 Europe Epilepsy Therapeutics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 46 Europe Epilepsy Therapeutics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 47 Europe Epilepsy Therapeutics Market Forecast by Drug Class, 2024-2034 (US$ Million, AGR %)
Figure 48 Europe Epilepsy Therapeutics Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 49 Europe Epilepsy Therapeutics Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 50 Europe Epilepsy Therapeutics Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 51 Germany Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 52 France Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 53 UK Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 54 Italy Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 55 Spain Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 56 Sweden Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 57 Switzerland Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 58 Rest of Europe Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 59 Asia Pacific Epilepsy Therapeutics Market Attractiveness Index
Figure 60 Asia Pacific Epilepsy Therapeutics Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 61 Asia Pacific Epilepsy Therapeutics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 62 Asia Pacific Epilepsy Therapeutics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 63 Asia Pacific Epilepsy Therapeutics Market Forecast by Drug Class, 2024-2034 (US$ Million, AGR %)
Figure 64 Asia Pacific Epilepsy Therapeutics Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 65 Asia Pacific Epilepsy Therapeutics Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 66 Asia Pacific Epilepsy Therapeutics Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 67 Japan Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 68 China Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 69 India Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 70 Australia Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 71 South Korea Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 72 Singapore Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 73 Taiwan Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 74 Rest of Asia Pacific Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 75 Latin America Epilepsy Therapeutics Market Attractiveness Index
Figure 76 Latin America Epilepsy Therapeutics Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 77 Latin America Epilepsy Therapeutics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 78 Latin America Epilepsy Therapeutics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 79 Latin America Epilepsy Therapeutics Market Forecast by Drug Class, 2024-2034 (US$ Million, AGR %)
Figure 80 Latin America Epilepsy Therapeutics Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 81 Latin America Epilepsy Therapeutics Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 82 Latin America Epilepsy Therapeutics Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 83 Brazil Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 84 Mexico Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 85 Argentina Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 86 Rest of Latin America Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 87 MEA Epilepsy Therapeutics Market Attractiveness Index
Figure 88 MEA Epilepsy Therapeutics Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 89 MEA Epilepsy Therapeutics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 90 MEA Epilepsy Therapeutics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 91 MEA Epilepsy Therapeutics Market Forecast by Drug Class, 2024-2034 (US$ Million, AGR %)
Figure 92 MEA Epilepsy Therapeutics Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 93 MEA Epilepsy Therapeutics Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 94 MEA Epilepsy Therapeutics Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 95 GCC Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 96 South Africa Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 97 Rest of MEA Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 98 Eisai, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 99 Eisai, Inc.: Regional Market Shares, 2022
Figure 100 GlaxoSmithKline (GSK): Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 101 GlaxoSmithKline (GSK): R&D, 2017-2022 (US$ Million, AGR%)
Figure 102 GlaxoSmithKline (GSK): Regional Market Shares, 2022
Figure 103 Pfizer Inc: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 104 Pfizer Inc: R&D, 2017-2022 (US$ Million, AGR%)
Figure 105 Pfizer Inc: Regional Market Shares, 2022
Figure 106 Sanofi: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 107 Sanofi: R&D, 2017-2022 (US$ Million, AGR%)
Figure 108 Sanofi: Regional Market Shares, 2022
Figure 109 UCB S.A.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 110 UCB S.A.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 111 UCB S.A.: Regional Market Shares, 2022
Figure 112 Novartis AG: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 113 Novartis AG: R&D, 2017-2022 (US$ Million, AGR%)
Figure 114 Novartis AG: Regional Market Shares, 2022
Figure 115 Merck KGaA: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 116 Merck KGaA: R&D, 2017-2022 (US$ Million, AGR%)
Figure 117 Merck KGaA: Regional Market Shares, 2022
Figure 118 Neurocrine Biosciences Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 119 Neurocrine Biosciences Inc.: R&D, 2017-2022 (US$ Million, AGR%)
List of Companies Profiled in the Report
Eisai, Inc.
GlaxoSmithKline (GSK)
GW Pharma
Merk KGaA
Neurocrine Biosciences, Inc.
Novartis AG
Ovid Therapeutics
Pfizer Inc
Praxis Precision Medicines
Sanofi
UCB S.A.
List of Other Companies Mentioned in the Report
Accure Therapeutics
Aculys Pharma, Inc.
AstraZeneca
BenevolentAI,
DTx Pharma
Exscientia
Flynn Pharma Ltd.
Graviton Bioscience Corporation
GRIN Therapeutics
IAMA Therapeutics
Janssen
Jazz Pharma
Ligand Pharmaceuticals
m8 Pharmaceuticals
Mabwell Therapeutics
Marinus Pharma
NaviFUS Corp.
NeuExcell Therapeutics Group
Neurelis, Inc
Neurona Therapeutics, Inc.
Novartis AG
Paladin Labs
Pandion Therapeutics
Pharmanovia
Polpharma Biologics
PsychoGenics
Takeda
Tenacia Biotechnology Co. Ltd.
United BioSource Corp
Veriton Pharma
Voyager Therapeutics
Xenon Pharmaceuticals
Zentiva
Zogenix, Inc.
Zydus Lifesciences
List of Associations Mentioned in the Report
Duke University
Epilepsy Foundation
European Medicines Agency
European Union
Francis Crick Institute
Freie Universität
Indian Epilepsy Society (IES)
International Bureau for Epilepsy (IBE)
International League against Epilepsy (ILAE)
Macquarie University Dementia Research Centre
Medicines and Healthcare Products Regulatory Agency (MHRA)
Ministry of Home Affairs (MHA)
National Health Service (NHS)
National Institute of Surveillance of Medicines and Foods (INVIMA)
National Sanitary Surveillance Agency (ANVISA)
New York University
Oregon Health & Science University
Queensland University of Technology
The University of New Mexico Hospital
The University of Utah
United States Food and Drug Administration (USFDA)
U.S. Food and Drug Administration
Washington University School of Medicine
World Health Organization (WHO)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
